Business
Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory
Burlington, Ontario--(Newsfile Corp. - March 26, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology leader specializing in innovative oral thin film drug delivery, is pleased to provide shareholders with a strategic update highlighting its continued execution, operational resilience, and expanding global footprint.In an environment marked by global market volatility and geopolitical uncertainty, RDT is uniquely positioned with a...
About this update from Rapid Dose Therapeutics Corp
[{"type":"text","content":"Burlington, Ontario--(Newsfile Corp. - March 26, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology leader specializing in innovative oral thin film drug delivery, is pleased to provide shareholders with a strategic update highlighting its continued execution, operational resilience, and expanding global footprint.","length":401,"tagName":"p"},{"type":"text","content":"In an environment marked by global market volatility and geopolitical uncertainty, RDT is uniquely positioned with a business model that remains largely insulated from external disruptions. The Company's operations are not dependent on oil-linked inputs or global shipping constraints, and its cost structure is primarily composed of stable, fixed components. This positioning enables RDT to maintain operational continuity and focus squarely on long-term value creation.","length":475,"tagName":"p"},{"type":"text","content":"Since the beginning of 2026, RDT has achieved several meaningful milestones that further de-risk its growth strategy and strengthen its position across key international markets.","length":178,"tagName":"p"},{"type":"text","content":"Key Strategic Developments","length":26,"tagName":"p"},{"type":"text","content":"Global Intellectual Property Expansion – India Patent GrantRDT, alongside its partner Aavishkar Oral Strips Pvt. Ltd., has secured a significant patent (IN 582202) from the Indian Patent Office for its Nicotine Bilayer Oral Film. This achievement enhances the Company's intellectual property portfolio within one of the world's fastest-growing nicotine alternative markets and reinforces its broader global IP strategy under the Patent Cooperation Treaty framework with potential protection across 158 jurisdictions worldwide. Link: Newsfile.","length":556,"tagName":"p"},{"type":"text","content":"Advancing Global Tobacco CollaborationThe Company continues to build momentum in its fourth year of collaboration with a major global tobacco partner. Ongoing pharmacokinetic (PK) trials are designed to demonstrate that RDT's QuickStrip™ nicotine formulation can replicate the rapid absorption profile of traditional cigarettes—delivering effective craving management without the harmful effects of combustion. Link: RDT.","length":426,"tagName":"p"},{...